NorthWest Biotherapeutics Inc (NWBO)

[dstock07734]

This BCG discussion is boring. I would give you credit if you can enlighten me what the replacement could be. I doubt you can.

Let's talk about something more fun. Here are the two trials and the publications on the trial results.

One trial is the combination of CYT107 with Provenge on prostate cancer. The other one is the combination of CYT107 with DC vaccine on three tough pediatric sarcomas either metastasized or recurrent. Note for the latter trial, the pulsing technology which can load DCs with hundreds of tumor-associated antigens must be the same one used in the p3 trial. 100%!

Tell me why the efficacy from the first trial is definitely not as extraordinary as the second trial. I can tell you the reason. Dendreon's pulsing technology cannot make DCs load as many as tumor-associated antigens as NWBO's. It's just that simple.

CYT107 After Vaccine Treatment (Provenge®) in Patients With Metastatic Castration-Resistant Prostate Cancer
https://clinicaltrials.gov/study/NCT01881867

IL-7 expands lymphocyte populations and enhances immune responses to sipuleucel-T in patients with metastatic castration-resistant prostate cancer (mCRPC)
https://pmc.ncbi.nlm.nih.gov/articles/PMC8404457/

Therapy to Treat Ewing's Sarcoma, Rhabdomyosarcoma or Neuroblastoma
https://clinicaltrials.gov/study/NCT00923351

Adjuvant Immunotherapy to Improve Outcome in High-Risk Pediatric Sarcomas
https://aacrjournals.org/clincancerres/article/22/13/3182/79179/Adjuvant-Immunotherapy-to-Improve-Outcome-in-High